Raymond James Financial Inc. acquired a new position in Cibus, Inc. (NASDAQ:CBUS – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 32,120 shares of the company’s stock, valued at approximately $89,000.
Other hedge funds have also recently made changes to their positions in the company. IFP Advisors Inc bought a new position in Cibus in the 4th quarter worth approximately $36,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Cibus during the third quarter valued at approximately $44,000. Virtu Financial LLC purchased a new position in shares of Cibus in the third quarter worth $48,000. HighTower Advisors LLC boosted its position in shares of Cibus by 20.6% during the third quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock worth $52,000 after acquiring an additional 2,750 shares during the last quarter. Finally, Barclays PLC grew its stake in Cibus by 287.2% during the third quarter. Barclays PLC now owns 20,269 shares of the company’s stock valued at $66,000 after acquiring an additional 15,034 shares in the last quarter. Institutional investors own 33.81% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have commented on CBUS shares. Canaccord Genuity Group decreased their price target on shares of Cibus from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Cibus in a research report on Friday, March 21st.
View Our Latest Analysis on Cibus
Cibus Stock Performance
Shares of CBUS opened at $1.81 on Friday. The stock has a market capitalization of $59.46 million, a PE ratio of -0.08 and a beta of 1.83. The company’s fifty day moving average is $2.10 and its 200 day moving average is $3.02. Cibus, Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $19.56.
Cibus (NASDAQ:CBUS – Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.19). The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.13 million. Cibus had a negative return on equity of 28.17% and a negative net margin of 10,724.78%. As a group, research analysts forecast that Cibus, Inc. will post -2.96 earnings per share for the current year.
About Cibus
(Free Report)
Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Read More
Want to see what other hedge funds are holding CBUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cibus, Inc. (NASDAQ:CBUS – Free Report).
Receive News & Ratings for Cibus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cibus and related companies with MarketBeat.com’s FREE daily email newsletter.
